Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics, Inc.

Edgewise Therapeutics develops novel therapeutics for serious skeletal and cardiac muscle diseases with unmet medical needs.

COM:EDGEWISETX

Edgewise Therapeutics

Last Close

26.02

14/02 21:00

Market Cap

2.01B

Beta: -

Volume Today

1.22M

Avg: -

People Not Available